Trial 9L-16-4


A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) In Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 Or High Risk Myelodysplastic Syndrome (MDS)

Type: Treatment
Phase: Phase I/II
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Sondra Ortiz, Coordinator, Anastasia Martynova, D.M., Donna Fernando, Coordinator, Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.